Physician profile
Ruby Camarena
NPI 1144203480
$3,236.84
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $508 · 2021: $369 · 2022: $136 · 2023: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $627.55 | 2019-2023 | |
| Glaxosmithkline, LLC. | $505.82 | 2019-2023 | Pediarix, Rotarix, Bexsero |
| Janssen Pharmaceuticals, INC | $427.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $376.83 | 2019-2020 | |
| Lilly USA, LLC | $197.92 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.87 | 2019-2020 | |
| Janssen Biotech, INC. | $106.75 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.54 | 2019-2023 | |
| Novo Nordisk INC | $87.54 | 2021-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.59 | 2019-2020 | |
| Viiv Healthcare Company | $67.98 | 2019-2020 | |
| Amgen INC. | $63.09 | 2020-2021 | |
| Pfizer INC. | $44.30 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $40.99 | 2019-2020 | |
| Therapeuticsmd, INC. | $40.16 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $35.05 | 2022-2023 | Slynd |
| Mylan Pharmaceuticals INC. | $33.39 | 2021-2022 | |
| Lupin INC. | $33.30 | 2020 | |
| Sanofi Pasteur INC. | $27.68 | 2019-2020 | |
| Abbvie INC. | $25.71 | 2023 | Vraylar |
| Amarin Pharma, INC. | $25.45 | 2019 | |
| Phadia US INC. | $19.23 | 2020 | |
| Evofem Biosciences, INC. | $18.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.56 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.86 | 2022 | |
| Becton, Dickinson and Company | $14.18 | 2019 | |
| Dynavax Technologies Corporation | $13.71 | 2019 | |
| Hologic INC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Camarena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.